Investigating the effects of mesenchymal stromal cell vesicles on blood cell development in myelofibrosis patients
Microenvironment Cross-talk: Role of Extracellular Vesicles Derived From Mesenchymal Stromal Cells of Patients With Primary Myelofibrosis in Modifying Functional Activities of CD34+ Hematopoietic Progenitor Cells
Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06896344
This study is testing how special cells from patients with myelofibrosis affect the growth of blood cells to see if they behave differently than those from healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia (other) |
| Drugs / interventions | Ruxolitinib |
| Locations | 1 site (Pavia, Pavia) |
| Trial ID | NCT06896344 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore how mesenchymal stromal cells (MSCs) from patients with primary myelofibrosis (PMF) influence the maturation of CD34+ hematopoietic progenitor cells. The study will analyze the differences in MSCs from PMF patients compared to healthy donors and how these differences affect the signaling pathways involved in blood cell development. By utilizing in vitro cultures, the researchers will assess the impact of MSC-derived extracellular vesicles on CD34+ cells, particularly those expressing the JAK2 V617F mutation. The findings could provide insights into the bone marrow microenvironment's role in PMF pathology.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with primary myelofibrosis and carrying the JAK2 V617F mutation.
Not a fit: Patients with primary myelofibrosis who have undergone splenectomy or bone marrow transplant, or those with other concurrent pathologies, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and potential new therapeutic strategies for managing primary myelofibrosis.
How similar studies have performed: While the specific approach of this study is novel, previous studies have shown the importance of MSCs in hematological malignancies, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with PMF * JAK2 V617F+ (either homozygous or heterozygous) * Out of therapy * At least 18 years old Exclusion Criteria: * PMF combined to other pathologies * Previous splenectomy * Previous bone marrow transplant
Where this trial is running
Pavia, Pavia
- Fondazione IRCCS Policlinico San Matteo di Pavia — Pavia, Pavia, Italy (RECRUITING)
Study contacts
- Principal investigator: Margherita Massa, PhD — IRCCS Policlinico San Matteo Foundation
- Study coordinator: Margherita Massa, PhD
- Email: m.massa@smatteo.pv.it
- Phone: +39 0382502703
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Primary Myelofibrosis, CD34, extracellular vesicles